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 5 
Sir, we thank Dr Mounier and colleagues for their response 1 to our comments. 2 We 6 
consider that they have not fully addressed three important areas: laboratory methods, 7 
clinical evidence of efficacy and longevity of effect. 8 
Mounier et al say that most of our laboratory experiments “rely on 5min to 1h bacterial 9 
challenge”… “this model of short term exposure” …but in our papers we expose the 10 
antimicrobial catheters for 1 h every 2 weeks for 42 days in constant flow conditions to 11 
mimic repeated bacterial challenge of the external ventricular drain (EVD). 3 This could 12 
hardly be said to be a short - term exposure. The 1h contact for bacterial attachment 13 
resulted in heavy colonization of control catheters; the antimicrobial catheters remained 14 
free of colonization even after 42 days, which is inconsistent with their zone plate findings. 15 
Mounier et al say that clinical evidence does not support claims of benefit from 16 
antimicrobial EVD catheters. One study by Ramirez et al which they cited showed Bactiseal 17 
failures only when Acinetobacter baumannii or Klebsiella pneumoniae were involved, and 18 
this is understandable as Bactiseal has no activity against Gram negative bacilli 4. Some of 19 
the other studies cited that show no difference in infection rate also used systemic 20 
antibiotics throughout the EVD period of use, 5,6,7 and this is acknowledged to reduce 21 
ventriculitis rates. However, the risk of this approach is also evidenced in the literature, the 22 
study by Wong et al (REF) being an example, where antimicrobial EVD catheters without 23 
systemic antibiotics were compared with plain catheters with systemic antibiotics. While the 24 
ventriculitis rates were low (1.1% and 3.2% respectively), there were three cases of 25 
Clostridioides difficile infection in the antibiotics group (with one total colectomy) but none 26 
in the antimicrobial catheter group.  The message from these studies is not that there is no 27 
difference in ventriculitis rate between Bactiseal EVD and plain catheters, but that Bactiseal 28 
EVD gives the same protection as longterm systemic antibiotics but without the adverse 29 
effects.  30 
Finally, Mounier et al say that the activity of antimicrobial EVDs decreases with time in use. 31 
This is to be expected, but as we pointed out previously, 2 the amount of antimicrobial 32 
released should not be taken to indicate potential protective activity. We have shown that 33 
the amount of rifampicin and clindamycin decreases sharply from 3mg/L and 25mg/L resp 34 
on Day 1 to 0.8mg/L and 1.2mg/L resp on Day 2, but 0.01mg/L and 0.2mg/L are still being 35 
released on Day 21. 8 It is important to point out that these concentrations are those 36 
released into surrounding fluid phase and are not indicative of the continuing surface 37 
activity at these time points. Indeed, the protective activity was sustained at these time 38 
points. 39 
Antimicrobial biomaterials are still imperfectly studied and incompletely understood, but it 40 
is important to use assessment methods that are as nearly relevant as possible to clinical 41 
use conditions. 42 
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